DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives $12.00 Average Target Price from Analysts

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $12.00.

A number of equities research analysts have issued reports on DMAC shares. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of DiaMedica Therapeutics in a research note on Tuesday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen upgraded DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th.

Institutional Trading of DiaMedica Therapeutics

Several large investors have recently modified their holdings of DMAC. Bank of New York Mellon Corp bought a new position in DiaMedica Therapeutics in the 2nd quarter worth approximately $829,000. Squarepoint Ops LLC bought a new position in DiaMedica Therapeutics in the 2nd quarter valued at $1,023,000. AWM Investment Company Inc. acquired a new stake in shares of DiaMedica Therapeutics in the 2nd quarter valued at $253,000. Bank of America Corp DE increased its stake in shares of DiaMedica Therapeutics by 62.5% in the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock valued at $290,000 after buying an additional 16,446 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of DiaMedica Therapeutics during the first quarter worth $356,000. 10.12% of the stock is owned by institutional investors.

DiaMedica Therapeutics Stock Performance

DMAC stock opened at $7.78 on Friday. DiaMedica Therapeutics has a 1 year low of $5.24 and a 1 year high of $10.42. The stock’s 50 day moving average price is $6.73 and its 200 day moving average price is $6.60. The firm has a market cap of $419.58 million, a P/E ratio of -10.81 and a beta of 0.98.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. On average, research analysts predict that DiaMedica Therapeutics will post -0.84 earnings per share for the current year.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases with limited therapeutic options. The company’s research is centered on therapies intended to address neurological and kidney-related conditions.

DiaMedica’s lead product candidate is rinvecalin, also known as DM199, a recombinant form of human tissue kallikrein-1. The company is evaluating rinvecalin as a potential treatment for acute ischemic stroke and kidney diseases, including conditions involving impaired renal function.